Seven months of disease control in patients with nowhere else to turn
At the crossroads of resistance and hope, Akeso presented data in April 2026 suggesting that a three-drug combination anchored by cadonilimab can meaningfully slow the advance of lung cancer in patients for whom standard immunotherapy has already failed. For those with advanced non-small cell lung cancer who have reached what medicine often treats as a dead end, a seven-month pause in disease progression and a 95.2 percent disease control rate represent something rarer than statistics — they represent time. The findings, shared at the European Lung Cancer Congress, extend the story of the world's first approved bispecific antibody into territory where few treatments have dared to follow.
- Patients with immunotherapy-resistant advanced lung cancer face a clinical wall — prior treatments have failed, options are scarce, and prognosis is often measured in weeks rather than years.
- Akeso's triple combination of cadonilimab, anlotinib, and docetaxel disrupts that grim calculus, achieving disease control in nearly all trial participants and tumor shrinkage in one in four.
- The regimen's tolerability sharpens its promise — only 14 percent of patients experienced severe side effects, and no treatment-related deaths occurred, a critical threshold for a population already weakened by disease and prior therapy.
- Patients who achieved molecular-level clearance of circulating tumor DNA fared even better, with median progression-free survival extending to 9.1 months, hinting at a deeper biological response.
- Without a control group the trial carries inherent limitations, but consistent benefit across cancer subtypes and PD-L1 expression levels lends the findings a credibility that positions cadonilimab as a serious second-line contender.
When immunotherapy fails a lung cancer patient, medicine has rarely had a confident answer. At the 2026 European Lung Cancer Congress, Akeso presented data suggesting that answer may now be closer. Their drug cadonilimab, paired with anlotinib and docetaxel, was tested in patients with advanced non-small cell lung cancer who had already exhausted immunotherapy — a population with limited options and a difficult prognosis.
Across 21 months of follow-up, the triple combination produced a median progression-free survival of seven months in the overall group. More than half of patients remained progression-free at six months, the disease control rate reached 95.2 percent, and a quarter of patients saw their tumors actively shrink. Among those who achieved clearance of circulating tumor DNA — a sign the treatment was working at the molecular level — median progression-free survival extended to 9.1 months.
Equally important was what the treatment did not do. Severe adverse events occurred in only 14 percent of patients, and no one died from treatment-related causes. For people already weakened by advanced cancer and prior failed therapies, a regimen that works without overwhelming the body carries its own form of significance.
Cadonilimab, approved in 2022 as the world's first bispecific antibody cleared for cancer treatment, is engineered to engage two immune targets simultaneously, directing T cells against tumors from multiple angles. It has already shown value in hepatocellular carcinoma and gastric cancer resistant to prior immunotherapy. This lung cancer data extends that record into a disease area where resistance to standard treatment is increasingly common.
The trial was open-label and single-arm, without a comparison group — a limitation the researchers acknowledge. Yet the consistency of benefit across squamous cell and non-squamous subtypes, and across varying levels of PD-L1 expression, strengthens the case. For Akeso, the results mark cadonilimab's emergence as a potential second-line standard in a market defined by unmet need. For patients who have run out of first-line options, they mark something more personal: a concrete alternative where almost none existed before.
At the 2026 European Lung Cancer Congress in April, Akeso presented results that could reshape how doctors treat a particularly stubborn form of cancer: advanced lung cancer that has already resisted immunotherapy. The company's drug, cadonilimab, combined with two other medications—anlotinib and docetaxel—showed it could slow disease progression and control tumors in patients who had nowhere else to turn.
These patients represent a clinical dead end. They have advanced non-small cell lung cancer that has spread locally or throughout the body. They've already received immunotherapy drugs designed to unleash the immune system against cancer, and those drugs failed. Standard options at that point are limited and often grim. Akeso's trial followed 21 months of patient outcomes to see whether this three-drug combination could offer something better.
The numbers suggest it can. In the overall patient group, the median time before cancer progressed was seven months—not a cure, but a meaningful pause. More than half the patients, 55.7 percent, remained progression-free at six months. The disease control rate reached 95.2 percent, meaning the cancer either shrank or at least stopped growing in nearly all participants. One in four patients saw their tumors actually shrink, a response rate of 26.2 percent. When patients achieved complete clearance of circulating tumor DNA—essentially erasing detectable cancer cells from their bloodstream—their median progression-free survival stretched to 9.1 months, suggesting the regimen was working at the molecular level.
What makes this particularly noteworthy is the safety profile. The triple combination produced severe side effects in only 14 percent of patients. No one died from treatment-related causes. For a population already weakened by advanced cancer and prior failed therapies, tolerability matters as much as efficacy. Doctors need a drug that works without destroying the patient in the process.
Cadonilimab itself is not new to the market. Approved in 2022, it holds the distinction of being the world's first bispecific antibody approved for cancer treatment—a drug engineered to grab onto two different targets simultaneously, essentially recruiting the immune system's T cells to attack cancer cells from multiple angles. The company has already demonstrated its value in other hard-to-treat cancers, including hepatocellular carcinoma and gastric cancer that resisted prior immunotherapy. This lung cancer data extends that track record into a new disease area where resistance to standard immunotherapy is increasingly common.
The trial was prospective, open-label, and single-arm—meaning patients knew they were receiving the combination, and there was no control group for comparison. That's a limitation worth noting, though the consistency of benefit across patient subgroups lends credibility to the findings. Patients with squamous cell lung cancer showed a median progression-free survival of 7.5 months; those with higher PD-L1 expression, a marker sometimes associated with better immunotherapy response, achieved 7.4 months. The regimen worked across the board.
For Akeso, these results position cadonilimab as a potential second-line treatment option—the drug you turn to when first-line therapy has failed. That's a significant market opportunity in a disease where resistance to immunotherapy is becoming routine. For patients with metastatic lung cancer who have exhausted their initial options, it represents a concrete alternative where few existed before. The company is now working on a pipeline of over 50 innovative assets across cancer and other diseases, but this data suggests cadonilimab's role in oncology is far from finished.
Notable Quotes
Cadonilimab-based regimens have demonstrated clinically meaningful benefit across all patient populations regardless of PD-L1 expression status, addressing a significant unmet medical need— Akeso announcement
The Hearth Conversation Another angle on the story
Why does it matter that this drug works in patients who've already failed immunotherapy? Isn't that just a niche population?
It's actually the opposite. As immunotherapy becomes standard first-line treatment for lung cancer, more and more patients will eventually progress through it. Right now, those patients have very few options. This data shows cadonilimab can extend their survival meaningfully—seven months of progression-free time is real time for someone with metastatic cancer.
The safety profile seems unusually clean for a triple combination. Only 14 percent severe side effects. How does that happen?
Cadonilimab has a track record of being well-tolerated in other cancers. The company seems to have chosen companion drugs that don't overlap toxicities. When you're treating patients who are already weakened by advanced disease, that matters enormously. A drug that works but destroys the patient isn't actually a solution.
The circulating tumor DNA data is interesting—patients who cleared it had 9.1 months progression-free survival versus 7.0 overall. Is that cause and effect, or just a marker of who responds better?
It's likely both. ctDNA clearance is a marker of deep anti-tumor activity, but it's also probably selecting for patients whose biology is more responsive to this particular regimen. Either way, it tells us the drug is working at the molecular level, not just shrinking tumors on imaging.
What's the actual clinical significance of a 7-month median progression-free survival? Is that good?
In this population—patients who've already failed immunotherapy—it's quite good. These are people with limited options. Seven months of disease control, with a 95 percent disease control rate overall, gives them time. Time for quality of life, time for family, potentially time for other treatments to become available.
Does this change how doctors will treat lung cancer?
It should. This gives oncologists a concrete option for the second-line setting in immunotherapy-resistant disease. Whether it becomes standard will depend on how it performs in larger trials and how it compares to other options, but the data is compelling enough to shift thinking about what's possible in this difficult population.